Immune cells: more than simple carriers for systemic delivery of oncolytic viruses
Oncolytic virotherapy on its own has numerous drawbacks, including an inability of the virus to actively target tumor cells and systemic toxicities at the high doses necessary to effectively treat tumors. Addition of immune cell-based carriers of oncolytic viruses holds promise as a technique in whi...
Main Authors: | , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354653/ |
id |
pubmed-4354653 |
---|---|
recordtype |
oai_dc |
spelling |
pubmed-43546532015-03-10 Immune cells: more than simple carriers for systemic delivery of oncolytic viruses Eisenstein, Samuel Chen, Shu-Hsia Pan, Ping-Ying Review Oncolytic virotherapy on its own has numerous drawbacks, including an inability of the virus to actively target tumor cells and systemic toxicities at the high doses necessary to effectively treat tumors. Addition of immune cell-based carriers of oncolytic viruses holds promise as a technique in which oncolytic virus can be delivered directly to tumors in smaller and less toxic doses. Interestingly, the cell carriers themselves have also demonstrated antitumor effects, which can be augmented further by tailoring the appropriate oncolytic virus to the appropriate cell type. This review discusses the multiple factors that go into devising an effective, cell-based delivery system for oncolytic viruses. Dove Medical Press 2014-11-06 /pmc/articles/PMC4354653/ /pubmed/25767789 http://dx.doi.org/10.2147/OV.S47143 Text en © 2014 Eisenstein et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
repository_type |
Open Access Journal |
institution_category |
Foreign Institution |
institution |
US National Center for Biotechnology Information |
building |
NCBI PubMed |
collection |
Online Access |
language |
English |
format |
Online |
author |
Eisenstein, Samuel Chen, Shu-Hsia Pan, Ping-Ying |
spellingShingle |
Eisenstein, Samuel Chen, Shu-Hsia Pan, Ping-Ying Immune cells: more than simple carriers for systemic delivery of oncolytic viruses |
author_facet |
Eisenstein, Samuel Chen, Shu-Hsia Pan, Ping-Ying |
author_sort |
Eisenstein, Samuel |
title |
Immune cells: more than simple carriers for systemic delivery of oncolytic viruses |
title_short |
Immune cells: more than simple carriers for systemic delivery of oncolytic viruses |
title_full |
Immune cells: more than simple carriers for systemic delivery of oncolytic viruses |
title_fullStr |
Immune cells: more than simple carriers for systemic delivery of oncolytic viruses |
title_full_unstemmed |
Immune cells: more than simple carriers for systemic delivery of oncolytic viruses |
title_sort |
immune cells: more than simple carriers for systemic delivery of oncolytic viruses |
description |
Oncolytic virotherapy on its own has numerous drawbacks, including an inability of the virus to actively target tumor cells and systemic toxicities at the high doses necessary to effectively treat tumors. Addition of immune cell-based carriers of oncolytic viruses holds promise as a technique in which oncolytic virus can be delivered directly to tumors in smaller and less toxic doses. Interestingly, the cell carriers themselves have also demonstrated antitumor effects, which can be augmented further by tailoring the appropriate oncolytic virus to the appropriate cell type. This review discusses the multiple factors that go into devising an effective, cell-based delivery system for oncolytic viruses. |
publisher |
Dove Medical Press |
publishDate |
2014 |
url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354653/ |
_version_ |
1613197000285618176 |